Latest Insider Transactions at Merck & Co., Inc. (MRK)
This section provides a real-time view of insider transactions for Merck & Co., Inc. (MRK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Merck & Co., Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Merck & Co., Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 08
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
31,699
+23.49%
|
-
|
|
Jun 25
2019
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
216,718
-34.92%
|
$18,421,030
$85.67 P/Share
|
|
Jun 25
2019
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
216,718
+37.95%
|
-
|
|
May 10
2019
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
2,162
-3.0%
|
$168,636
$78.33 P/Share
|
|
May 10
2019
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
4,389
+5.75%
|
-
|
|
May 10
2019
|
Michael Fleming SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
517
-15.59%
|
$40,326
$78.33 P/Share
|
|
May 10
2019
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,509
+31.27%
|
-
|
|
May 10
2019
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
516
-11.79%
|
$40,248
$78.33 P/Share
|
|
May 10
2019
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,811
+29.27%
|
-
|
|
May 10
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
1,622
-7.24%
|
$126,516
$78.33 P/Share
|
|
May 10
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
3,292
+12.81%
|
-
|
|
May 07
2019
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Open market or private sale
|
Direct |
25,000
-27.0%
|
$1,925,000
$77.73 P/Share
|
|
May 07
2019
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+21.26%
|
$975,000
$39.29 P/Share
|
|
May 06
2019
|
Kenneth C Frazier Executive Chair |
SELL
Bona fide gift
|
Direct |
14,623
-1.83%
|
-
|
|
May 04
2019
|
Frank Clyburn EVP & Pres ? Human Health |
SELL
Payment of exercise price or tax liability
|
Direct |
938
-1.37%
|
$75,040
$80.0 P/Share
|
|
May 04
2019
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Exercise of conversion of derivative security
|
Direct |
1,904
+2.7%
|
-
|
|
May 04
2019
|
Michael Nally EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
370
-12.61%
|
$29,600
$80.0 P/Share
|
|
May 04
2019
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,298
+30.66%
|
-
|
|
May 04
2019
|
Jennifer Zachary EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,154
-37.32%
|
$172,320
$80.0 P/Share
|
|
May 04
2019
|
Jennifer Zachary EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,772
+50.0%
|
-
|
|
May 04
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-3.03%
|
$47,760
$80.0 P/Share
|
|
May 04
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Exercise of conversion of derivative security
|
Direct |
1,212
+5.79%
|
-
|
|
May 04
2019
|
Michael Fleming SVP Chief Ethics & Com Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
238
-11.64%
|
$19,040
$80.0 P/Share
|
|
May 04
2019
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
692
+25.28%
|
-
|
|
May 03
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
SELL
Open market or private sale
|
Direct |
35,000
-33.0%
|
$2,800,000
$80.0 P/Share
|
|
May 03
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+24.81%
|
$1,365,000
$39.29 P/Share
|
|
Mar 25
2019
|
Robert M Davis Chairman, CEO & President |
SELL
Open market or private sale
|
Direct |
192,572
-58.31%
|
$15,790,904
$82.38 P/Share
|
|
Mar 25
2019
|
Robert M Davis Chairman, CEO & President |
BUY
Exercise of conversion of derivative security
|
Direct |
192,572
+36.83%
|
$11,169,176
$58.22 P/Share
|
|
Mar 20
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
192,736
-19.46%
|
$15,804,352
$82.05 P/Share
|
|
Mar 20
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
192,736
+16.29%
|
$7,516,704
$39.29 P/Share
|
|
Mar 13
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
18,725
-2.29%
|
$1,535,450
$82.0 P/Share
|
|
Mar 13
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
18,725
+2.24%
|
$730,275
$39.29 P/Share
|
|
Mar 05
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
6,961
-0.87%
|
$570,802
$82.0 P/Share
|
|
Mar 05
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
6,961
+0.86%
|
$271,479
$39.29 P/Share
|
|
Mar 04
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
13,144
-1.62%
|
$1,077,808
$82.01 P/Share
|
|
Mar 04
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
13,144
+1.6%
|
$512,616
$39.29 P/Share
|
|
Feb 25
2019
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
10,380
+14.37%
|
$830,400
$80.38 P/Share
|
|
Feb 25
2019
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
4,017
+5.72%
|
$321,360
$80.38 P/Share
|
|
Feb 25
2019
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
30,610
+18.19%
|
$2,448,800
$80.38 P/Share
|
|
Feb 25
2019
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
13,507
+16.06%
|
$1,080,560
$80.38 P/Share
|
|
Feb 25
2019
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
105,765
+11.71%
|
$8,461,200
$80.38 P/Share
|
|
Feb 25
2019
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,747
+13.66%
|
$699,760
$80.38 P/Share
|
|
Feb 25
2019
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+11.18%
|
$186,400
$80.38 P/Share
|
|
Feb 25
2019
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,527
+50.0%
|
$122,160
$80.38 P/Share
|
|
Feb 25
2019
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
32,937
+15.81%
|
$2,634,960
$80.38 P/Share
|
|
Feb 22
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
53,961
-7.23%
|
$4,316,880
$80.02 P/Share
|
|
Feb 22
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
53,961
+6.75%
|
$2,104,479
$39.29 P/Share
|
|
Feb 21
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
41,992
-5.72%
|
$3,359,360
$80.0 P/Share
|
|
Feb 21
2019
|
Kenneth C Frazier Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
41,992
+5.41%
|
$1,637,688
$39.29 P/Share
|
|
Feb 19
2019
|
Kenneth C Frazier Executive Chair |
SELL
Open market or private sale
|
Direct |
42,700
-5.81%
|
$3,416,000
$80.02 P/Share
|